Immunometabolic regulation in gouty arthritis: current evidence, mechanistic insights, and remaining challenges
-
By
-
Xingzheng Liu
-
Xingrui Yan
-
Tao Wang
-
TingTing Luo
-
Shengqin Yang
-
Yixin Fang
-
Xiumin Chen
-
Runyue Huang
-
Maojie Wang
-
Xiaodong Wu
-
July 6, 2026
-
Clinical Scorecard: Immunometabolic Factors in Gouty Arthritis: Current Insights, Mechanisms, and Ongoing Challenges
At a Glance
| Category | Detail |
|---|
| Condition | Gouty Arthritis |
| Key Mechanisms | Monosodium urate (MSU) crystal deposition, NLRP3 inflammasome activation, IL-1β signaling |
| Target Population | Individuals with hyperuricemia and recurrent gout flares |
| Care Setting | Clinical management of inflammatory joint conditions |
Key Highlights
- Gouty arthritis is characterized by acute inflammation due to MSU crystal deposition.
- The NLRP3 inflammasome and IL-1β are central to the inflammatory response in gout.
- Immunometabolic pathways influence the intensity and duration of gouty inflammation.
- Asymptomatic crystal deposition does not always lead to clinical flares.
- Systemic metabolic abnormalities may affect susceptibility to recurrent flares.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of gouty arthritis is based on clinical presentation and identification of MSU crystals.
Management
- Current anti-inflammatory strategies target the NLRP3 inflammasome and IL-1β signaling.
Monitoring & Follow-up
- Monitor uric acid levels and assess for recurrent flares.
Risks
- Chronic gout may lead to joint deformity and functional impairment.
Patient & Prescribing Data
Patients with gout and associated comorbidities such as obesity and metabolic syndrome.
Management should consider systemic metabolic factors influencing inflammation.
Clinical Best Practices
- Integrate immunometabolic understanding into the management of gouty arthritis.
- Consider patient-specific factors that may influence the inflammatory response.
Related Resources & Content
